JPJames Robert Platt

James Robert Platt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James Robert Platt has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Response to letter

    by James Robert Platt

  • Open Access

    CT staging performance in an international trial of neoadjuvant chemotherapy for locally advanced colon cancer

    by James R Platt, Faye Elliott, Kelly Handley, Laura Magill, Philip Quirke, Matthew T Seymour, Nicholas P West, Dion Morton, Jenny Seligmann, Damian J M Tolan

    Objectives: In the Fluorouracil, Oxaliplatin and Targeted Receptor pre-Operative Therapy (FOxTROT) trial, neoadjuvant chemotherapy (NAC) significantly reduced recurrence risk, compared to upfront surgery, in locally advanced colon cancer. This analysis evaluates the correlation between radiological and pathological staging within the trial to support the adoption of CT-based patient selection. Methods: In this preplanned analysis of prospectively collected data, local radiological and pathological staging were compared in upfront surgery participants. T stage, N stage, and extramural venous invasion (EMVI) status were evaluated using overall agreement, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Subgroup analyses explored the impact of mismatch repair status and tumour side. Results: A total of 354 participants were included. T stage agreement was 63.0%; T3 and T4 tumours were correctly identified in 78.9% and 41.1% of participants, respectively. The PPV for T3-4 status was 94.5%. N stage agreement was 39.8%; for N status (positive vs. negative), overall agreement, sensitivity, specificity, PPV, and NPV were 54.1%, 81.1%, 26.0%, 53.2%, and 57.1%, respectively. For EMVI, these values were 54.9%, 71.0%, 41.2%, 50.7%, and 62.5%, respectively. Accuracy metrics did not differ significantly by tumour side or mismatch repair status. Conclusions: CT effectively predicted T3-4 status with minimal overstaging, but performed poorly for individual T stage, N stage, and EMVI. We propose radiological T3-4 status should be adopted as the primary biomarker for neoadjuvant patient selection, with molecular biomarkers to guide treatment choice. Advances in knowledge: In this multicentre trial, local radiologists accurately identified T3-4 status to select participants for NAC, indicating utility for future neoadjuvant trials and clinical practice.


  • Safe prescribing in cancer patients during the COVID‐19 pandemic and outcomes following restart of cancer care following SARS‐CoV‐2 infection: The COV‐SPOT initiative

    by Nathan Appanna, Rosie Mew, Sophie Williams, Thomas Starkey, Grisma Patel, Laura Hudson, Emma Burke, Francesca Aquilina, Caroline Harnett, Harrison Boult, et al.

    SARS‐CoV‐2 continues to spread across the world as a highly transmissible endemic disease. For many cancer patients, SARS‐CoV‐2 infection is unavoidable. It continues to disrupt cancer care, causing treatment delays and major psycho‐socio‐medical issues. At present, there is limited evidence on safe prescribing of anti‐cancer therapy, and safe treatment restart following SARS‐CoV‐2 infection. We conducted a prospective cohort study involving 406 COVID‐19‐positive cancer patients across five UK cancer centres and collected data on delay durations, COVID‐19 symptoms and mortality, to ascertain the effect of treatment interruptions. Patients were studied between May 2022 and March 2023, during which Omicron variants of SARS‐CoV‐2 were predominant. Mean treatment interruption was 12.7 days (standard deviation 47.3 days). Upon resuming anti‐cancer therapy, 8.5% experienced COVID‐19 symptom progression, and 1.2% succumbed to COVID‐19‐related mortality. Patients with haematological cancers had a 3.4‐fold increased risk of severe symptoms at 4 weeks compared to solid tumour patients. Higher symptom burden at COVID‐19 diagnosis was associated with a 3.0‐fold increase in symptom severity at 4 weeks following treatment restart. At 8 weeks following restart, 2.1% had increased morbidity or mortality. We highlight the ongoing impact of COVID‐19 on patients and cancer care, and the risk of resuming cancer treatments in patients with symptomatic COVID‐19. Although the risk of mortality is relatively low upon treatment resumption, personalised approaches assessing cancer diagnosis and SARS‐CoV‐2 status are crucial. Treatments are also stopped due to other infectious conditions and our results could be reviewed in the context of yearly influenza pandemics.

  • Open Access

    Colon cancer biology and treatment in the era of precision oncology: A primer for Radiologists

    by James R. Platt, Stephanie Pennycook, Chand E. Muthoo, Alice C. Westwood, Russell Frood, Andrew D. Beggs, Andrew Scarsbrook, Jenny F. Seligmann, Damian J.M. Tolan


  • Open Access

    Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series

    by J.R. Platt, J. Allotey, E. Alouani, J. Glasbey, R. Intini, S. Lonardi, G. Mazzoli, A.M. Militello, D.P. Modest, J. Palle, et al.


  • Open Access

    The impact of mismatch repair status and systemic inflammatory markers on radiological staging in colon cancer

    by James R Platt, Jennifer Ansett, Jenny F Seligmann, Nicholas P West, Damian J M Tolan

    Objective: Mismatch repair (MMR) deficient (dMMR) colon cancer (CC) is distinct from MMR proficient (pMMR) CC, yet the impact of MMR status on radiological staging is unclear. The purpose of this study was to investigate how MMR status impacts CC CT staging. Methods: We retrospectively compared CT staging accuracy between dMMR and pMMR CC patients undergoing curative resection. Accuracy was assessed as individual tumour (T)/nodal (N) stages and as dichotomous “statuses” (T1/2 vs T3/4; N0 vs N1/2). Patient characteristics were analysed for factors to support staging. Results: There was no significant difference in overall staging accuracy between the dMMR (44 patients) and pMMR (57 patients) groups. dMMR tumours with incorrect N stage/“status” were more likely to be overstaged than pMMR tumours (90% vs 59%; p = 0.023 for “N status”). Platelet count, CRP and neutrophil count (AUC 0.76 (p = 0.0078), 0.75 (p = 0.034) and 0.70 (p = 0.044), respectively) were associated with “N status” in dMMR tumours. Conclusion: Whilst overall staging accuracy was similar between groups, incorrectly N staged dMMR tumours were more likely to be overstaged than pMMR tumours, risking inappropriate surgical or neoadjuvant treatment. We describe novel relationships between several inflammatory markers and pathological “N status” in dMMR CC, which if integrated into routine practice may improve CT staging accuracy. Advances in knowledge: Compared to pMMR CC, dMMR CC is at significant risk of N overstaging. Platelet count, CRP and neutrophil count are higher in dMMR CC patients with nodal metastases than those without, and their role in refining clinical staging requires further investigation.


  • Open Access

    A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)

    by Thomas Starkey, Maria C. Ionescu, Michael Tilby, Martin Little, Emma Burke, Matthew W. Fittall, Sam Khan, Justin K. H. Liu, James R. Platt, Rosie Mew, et al.

    Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.


  • Open Access

    Personalizing neoadjuvant chemotherapy for locally advanced colon cancer: protocols for the international phase III FOxTROT2 and FOxTROT3 randomized controlled trials

    by James R. Platt, Christopher J. M. Williams, Zoe Craig, David A. Cairns, James C. Glasbey, Dion Morton, Jenny Seligmann

    Aim: FOxTROT1 established a new standard of care for managing locally advanced colon cancer (CC) with neoadjuvant chemotherapy (NAC). Six weeks of neoadjuvant oxaliplatin and fluoropyrimidine (OxFp) chemotherapy was associated with greater 2‐year disease‐free survival (DFS) when compared with proceeding straight to surgery (STS). There is now a need to refine the use of NAC and identify those most likely to benefit. FOxTROT2 will aim to investigate NAC in older adults and those with frailty. FOxTROT3 will aim to assess whether intensified triplet NAC provides additional benefits over OxFp.Method: FOxTROT2 and FOxTROT3 are international, open‐label, phase III randomized controlled trials. Eligible patients will be identified by the multidisciplinary team. Patient age, frailty and comorbidities will be considered to guide trial entry. Participants will be randomized 2:1 to the intervention or control arm: 6 weeks of dose‐adapted neoadjuvant OxFp versus STS in FOxTROT2 and 6 weeks of neoadjuvant modified oxaliplatin, 5‐fluorouracil and irinotecan versus OxFp in FOxTROT3. The primary endpoint in FOxTROT2 is 3‐year DFS. In FOxTROT3, tumour regression grade and 3‐year DFS are co‐primary endpoints.Discussion: FOxTROT2 and FOxTROT3 will establish the FOxTROT platform, a key part of our long‐term strategy to develop neoadjuvant treatments for CC. FOxTROT2 will investigate NAC in a population under‐represented in FOxTROT1 and wider research. FOxTROT3 will assess whether it is possible to induce greater early tumour responses and whether this translates to superior long‐term outcomes. Looking ahead, the FOxTROT platform will facilitate further trial comparisons and extensive translational research to optimize the use of NAC in CC.


  • Contemporary smartphone and social media resources for patients with anal cancer: an unmet need

    by J. R. Platt, U. Nawaz, P. Coyne, B. Griffiths, R. R. W. Brady

  • #BCSM and #breastcancer: Contemporary cancer‐specific online social media communities

    by James R. Platt, Richard R. Brady

    Online health care communities are commonplace on social media. This report investigates the engagement and use of breast cancer‐specific hashtags: #BCSM and #breastcancer. With over 5 million Twitter impressions weekly and increased engagement around academic meetings and news releases, these communities connect a global population. Most participants are based in the USA and work in health care; however, there is also significant engagement from the general population. Improved understanding of online hashtag communities and their output will allow us to innovate and improve the utility of this popular medium for communication in breast cancer and other disease‐specific populations.